Alternative splicing: Regulation of HIV-1 multiplication as a target for therapeutic action: Minireview

FEBS Journal

Volumn 277, Issue 4, 2010, Pages 867-876

  Tazi, Jamal ^a   Bakkour, Nadia ^a   Marchand, Virginie ^b   Ayadi, Lilia ^b   Aboufirassi, Amina ^a   Branlant, Christiane ^b  

^a UNIV MONTPELLIER   (France)

^b UNIVERSITÉ DE LORRAINE   (France)

Author keywords

Alternative splicing; HIV 1; HnRNP proteins; Retroviral therapy; SR proteins

Indexed keywords

ANTIRETROVIRUS AGENT; ANTISENSE OLIGONUCLEOTIDE; CIS ACTING ELEMENT; COMPLEMENTARY RNA; EXPORTIN 1; GAG PROTEIN; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN; IDC16; INDOLE DERIVATIVE; MESSENGER RNA PRECURSOR; NEF PROTEIN; POLYPYRIMIDINE TRACT BINDING PROTEIN; REV PROTEIN; RNA BINDING PROTEIN; RNA POLYMERASE II; SMALL NUCLEAR RNA; TRANS ACTING FACTOR; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG; VIF PROTEIN; VIRUS DNA; VIRUS ENVELOPE PROTEIN; VIRUS RNA; VPR PROTEIN; VPU PROTEIN;

ALTERNATIVE RNA SPLICING; ANTISENSE THERAPY; BINDING SITE; DOWN REGULATION; DRUG ACTIVITY; DRUG SAFETY; GENE EXPRESSION; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; RNA SEQUENCE; SHORT SURVEY; SIGNAL TRANSDUCTION; SPLICEOSOME; VIRUS REPLICATION; VIRUS STRAIN;

ALTERNATIVE SPLICING; ANTI-RETROVIRAL AGENTS; BASE SEQUENCE; HIV INFECTIONS; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 76149107814     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/j.1742-4658.2009.07522.x     Document Type: Short Survey

References (50)

1. Fauci AS (2003) HIV and AIDS: 20 years of science. Nat Med 9, 839 843.
2. Barbaro G, Scozzafava A, Mastrolorenzo A Supuran CT (2005) Highly active antiretroviral therapy: current state of the art, new agents and their pharmacological interactions useful for improving therapeutic outcome. Curr Pharm Des 11, 1805 1843.
3. Deeks SG (2006) Antiretroviral treatment of HIV infected adults. Br Med J 332, 1489.
4. Kijak GH, Currier JR, Tovanabutra S, Cox JH, Michael NL, Wegner SA, Birx DL McCutchan FE (2004) Lost in translation: implications of HIV-1 codon usage for immune escape and drug resistance. AIDS Rev 6, 54 60.
5. Frankel AD Young JA (1998) HIV-1: fifteen proteins and an RNA. Annu Rev Biochem 67, 1 25.
6. McLaren M, Marsh K Cochrane A (2008) Modulating HIV-1 RNA processing and utilization. Front Biosci 13, 5693 5707.
7. Pollard VW Malim MH (1998) The HIV-1 Rev protein. Annu Rev Microbiol 52, 491 532.
8. Lutzelberger M, Reinert LS, Das AT, Berkhout B Kjems J (2006) A novel splice donor site in the gag-pol gene is required for HIV-1 RNA stability. J Biol Chem 281, 18644 18651.
9. Purcell DF Martin MA (1993) Alternative splicing of human immunodeficiency virus type 1 mRNA modulates viral protein expression, replication, and infectivity. J Virol 67, 6365 6378.
10. Stoltzfus CM Madsen JM (2006) Role of viral splicing elements and cellular RNA binding proteins in regulation of HIV-1 alternative RNA splicing. Curr HIV Res 4, 43 55.
11. Kim S, Ikeuchi K, Byrn R, Groopman J Baltimore D (1989) Lack of a negative influence on viral growth by the nef gene of human immunodeficiency virus type 1. Proc Natl Acad Sci USA 86, 9544 9548.
12. Klotman ME, Kim S, Buchbinder A, DeRossi A, Baltimore D Wong-Staal F (1991) Kinetics of expression of multiply spliced RNA in early human immunodeficiency virus type 1 infection of lymphocytes and monocytes. Proc Natl Acad Sci USA 88, 5011 5015.
13. O'Reilly MM, McNally MT Beemon KL (1995) Two strong 5′ splice sites and competing, suboptimal 3′ splice sites involved in alternative splicing of human immunodeficiency virus type 1 RNA. Virology 213, 373 385.
14. Si Z, Amendt BA Stoltzfus CM (1997) Splicing efficiency of human immunodeficiency virus type 1 tat RNA is determined by both a suboptimal 3′ splice site and a 10 nucleotide exon splicing silencer element located within tat exon 2. Nucleic Acids Res 25, 861 867.
15. Staffa A Cochrane A (1994) The tat/rev intron of human immunodeficiency virus type 1 is inefficiently spliced because of suboptimal signals in the 3′ splice site. J Virol 68, 3071 3079.
16. Bilodeau PS, Domsic JK, Mayeda A, Krainer AR Stoltzfus CM (2001) RNA splicing at human immunodeficiency virus type 1 3′ splice site A2 is regulated by binding of hnRNP A/B proteins to an exonic splicing silencer element. J Virol 75, 8487 8497.
17. Caputi M Zahler AM (2002) SR proteins and hnRNP H regulate the splicing of the HIV-1 tev-specific exon 6D. EMBO J 21, 845 855.
18. Jacquenet S, Mereau A, Bilodeau PS, Damier L, Stoltzfus CM Branlant C (2001) A second exon splicing silencer within human immunodeficiency virus type 1 tat exon 2 represses splicing of Tat mRNA and binds protein hnRNP H. J Biol Chem 276, 40464 40475.
19. Tange TO, Damgaard CK, Guth S, Valcarcel J Kjems J (2001) The hnRNP A1 protein regulates HIV-1 tat splicing via a novel intron silencer element. EMBO J 20, 5748 5758.
20. Zahler AM, Damgaard CK, Kjems J Caputi M (2004) SC35 and heterogeneous nuclear ribonucleoprotein A/B proteins bind to a juxtaposed exonic splicing enhancer/exonic splicing silencer element to regulate HIV-1 tat exon 2 splicing. J Biol Chem 279, 10077 10084.
21. Kammler S, Otte M, Hauber I, Kjems J, Hauber J Schaal H (2006) The strength of the HIV-1 3′ splice sites affects Rev function. Retrovirology 3, 89.
22. Caputi M, Mayeda A, Krainer AR Zahler AM (1999) hnRNP A/B proteins are required for inhibition of HIV-1 pre-mRNA splicing. EMBO J 18, 4060 4067.
23. Caputi M, Freund M, Kammler S, Asang C Schaal H (2004) A bidirectional SF2/ASF- and SRp40-dependent splicing enhancer regulates human immunodeficiency virus type 1 rev, env, vpu, and nef gene expression. J Virol 78, 6517 6526.
24. Marchand C, Pourquier P, Laco GS, Jing N Pommier Y (2002) Interaction of human nuclear topoisomerase I with guanosine quartet-forming and guanosine-rich single-stranded DNA and RNA oligonucleotides. J Biol Chem 277, 8906 8911.
25. Staffa A Cochrane A (1995) Identification of positive and negative splicing regulatory elements within the terminal tat-rev exon of human immunodeficiency virus type 1. Mol Cell Biol 15, 4597 4605.
26. Zhu J, Mayeda A Krainer AR (2001) Exon identity established through differential antagonism between exonic splicing silencer-bound hnRNP A1 and enhancer-bound SR proteins. Mol Cell 8, 1351 1361.
27. Madsen JM Stoltzfus CM (2005) An exonic splicing silencer downstream of the 3′ splice site A2 is required for efficient human immunodeficiency virus type 1 replication. J Virol 79, 10478 10486.
28. Domsic JK, Wang Y, Mayeda A, Krainer AR Stoltzfus CM (2003) Human immunodeficiency virus type 1 hnRNP A/B-dependent exonic splicing silencer ESSV antagonizes binding of U2AF65 to viral polypyrimidine tracts. Mol Cell Biol 23, 8762 8772.
29. Ropers D, Ayadi L, Gattoni R, Jacquenet S, Damier L, Branlant C Stevenin J (2004) Differential effects of the SR proteins 9G8, SC35, ASF/SF2, and SRp40 on the utilization of the A1 to A5 splicing sites of HIV-1 RNA. J Biol Chem 279, 29963 29973.
30. Saliou JM, Bourgeois CF, Ayadi-Ben ML, Ropers D, Jacquenet S, Marchand V, Stevenin J Branlant C (2009) Role of RNA structure and protein factors in the control of HIV-1 splicing. Front Biosci 14, 2714 2729.
31. Heinzinger NK, Bukinsky MI, Haggerty SA, Ragland AM, Kewalramani V, Lee MA, Gendelman HE, Ratner L, Stevenson M Emerman M (1994) The Vpr protein of human immunodeficiency virus type 1 influences nuclear localization of viral nucleic acids in nondividing host cells. Proc Natl Acad Sci USA 91, 7311 7315.
32. Kamata M, Nitahara-Kasahara Y, Miyamoto Y, Yoneda Y Aida Y (2005) Importin-alpha promotes passage through the nuclear pore complex of human immunodeficiency virus type 1 Vpr. J Virol 79, 3557 3564.
33. Kino T, Gragerov A, Slobodskaya O, Tsopanomichalou M, Chrousos GP Pavlakis GN (2002) Human immunodeficiency virus type 1 (HIV-1) accessory protein Vpr induces transcription of the HIV-1 and glucocorticoid-responsive promoters by binding directly to p300/CBP coactivators. J Virol 76, 9724 9734.
34. Kuramitsu M, Hashizume C, Yamamoto N, Azuma A, Kamata M, Yamamoto N, Tanaka Y Aida Y (2005) A novel role for Vpr of human immunodeficiency virus type 1 as a regulator of the splicing of cellular pre-mRNA. Microbes Infect 7, 1150 1160.
35. Zhang X Aida Y (2009) HIV-1 Vpr: a novel role in regulating RNA splicing. Curr HIV Res 7, 163 168.
36. Hallay H, Locker N, Ayadi L, Ropers D, Guittet E Branlant C (2006) Biochemical and NMR study on the competition between proteins SC35, SRp40, and heterogeneous nuclear ribonucleoprotein A1 at the HIV-1 Tat exon 2 splicing site. J Biol Chem 281, 37159 37174.
37. Karn J (1999) Tackling Tat. J Mol Biol 293, 235 254.
38. Li CJ, Friedman DJ, Wang C, Metelev V Pardee AB (1995) Induction of apoptosis in uninfected lymphocytes by HIV-1 Tat protein. Science 268, 429 431.
39. Berro R, Kehn K, de la Fuente C, Pumfery A, Adair R, Wade J, Colberg-Poley AM, Hiscott J Kashanchi F (2006) Acetylated Tat regulates human immunodeficiency virus type 1 splicing through its interaction with the splicing regulator p32. J Virol 80, 3189 3204.
40. Brigati C, Giacca M, Noonan DM Albini A (2003) HIV Tat, its targets and the control of viral gene expression. FEMS Microbiol Lett 220, 57 65.
41. Malim MH, Bohnlein S, Fenrick R, Le SY, Maizel JV Cullen BR (1989) Functional comparison of the Rev trans-activators encoded by different primate immunodeficiency virus species. Proc Natl Acad Sci USA 86, 8222 8226.
42. Kammler S, Leurs C, Freund M, Krummheuer J, Seidel K, Tange TO, Lund MK, Kjems J, Scheid A Schaal H (2001) The sequence complementarity between HIV-1 5′ splice site SD4 and U1 snRNA determines the steady-state level of an unstable env pre-mRNA. RNA 7, 421 434.
43. Woolaway K, Asai K, Emili A Cochrane A (2007) hnRNP E1 and E2 have distinct roles in modulating HIV-1 gene expression. Retrovirology 4, 28.
44. Asparuhova MB, Marti G, Liu S, Serhan F, Trono D Schumperli D (2007) Inhibition of HIV-1 multiplication by a modified U7 snRNA inducing Tat and Rev exon skipping. J Gene Med 9, 323 334.
45. Muller B Schumperli D (1997) The U7 snRNP and the hairpin binding protein: key players in histone mRNA metabolism. Semin Cell Dev Biol 8, 567 576.
46. Bakkour N, Lin YL, Maire S, Ayadi L, Mahuteau-Betzer F, Nguyen CH, Mettling C, Portales P, Grierson D, Chabot B et al. (2007) Small-molecule inhibition of HIV pre-mRNA splicing as a novel antiretroviral therapy to overcome drug resistance. PLoS Pathol 3, 1530 1539.
47. Keriel A, Mahuteau-Betzer F, Jacquet C, Plays M, Grierson D, Sitbon M Tazi J (2009) Protection against retrovirus pathogenesis by SR protein inhibitors. PLoS ONE 4, e4533.
48. Cartegni L Krainer AR (2003) Correction of disease-associated exon skipping by synthetic exon-specific activators. Nat Struct Biol 10, 120 125.
49. Skordis LA, Dunckley MG, Yue B, Eperon IC Muntoni F (2003) Bifunctional antisense oligonucleotides provide a trans-acting splicing enhancer that stimulates SMN2 gene expression in patient fibroblasts. Proc Natl Acad Sci USA 100, 4114 4119.
50. Ryther RC, Flynt AS, Phillips JA III. Patton JG (2005) siRNA therapeutics: big potential from small RNAs. Gene Ther 12, 5 11.